Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

903.90 +4.96 (+0.55%)

Streaming Delayed Price Updated: 10:34 AM EDT, Jun 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

July 24, 2025

From argenx SE

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

June 02, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

July 31, 2025

From argenx SE

Via GlobeNewswire

argenx Earnings Preview ↗

July 30, 2025

Via Benzinga

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

July 28, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

July 28, 2025

From Pomerantz LLP

Via GlobeNewswire

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

July 16, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗

July 07, 2025

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

July 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

July 02, 2025

Via Benzinga

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls ↗

June 30, 2025

FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.

Via Benzinga

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

June 30, 2025

From argenx SE

Via GlobeNewswire

Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention ↗

June 20, 2025

VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional.

Via Stocktwits

Topics Artificial Intelligence

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

June 20, 2025

From argenx SE

Via GlobeNewswire

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

June 16, 2025

Via Benzinga

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease

June 10, 2025

From argenx SE

Via GlobeNewswire

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025

From argenx SE

Via GlobeNewswire

argenx Announces Results of Annual General Meeting of Shareholders

May 28, 2025

From argenx SE

Via GlobeNewswire

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? ↗

May 27, 2025

HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.

Via Benzinga

This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

May 13, 2025

Via Benzinga

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗

May 11, 2025

The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?

Via Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

May 09, 2025

Via Benzinga

14 Analysts Have This To Say About argenx ↗

May 09, 2025

Via Benzinga

Argenx Shares Drop After Q1 Miss, But Retail Traders Call Sub-$550 ‘An Absolute Steal’ ↗

May 08, 2025

Despite the Q1 miss, management reiterated confidence in its long-term “Vision 2030” strategy, highlighting strong Vyvgart uptake in gMG and CIDP and the recent U.S. approval of a self-injection...

Via Stocktwits

Topics Earnings

Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings ↗

May 08, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.